Research and Clinical Trials

Title  
Hoffman-LaRoche GO30139: A Phase IB Study evaluating the safety and pharmacology of atezolimumab administered in combination with immunomodulatory agent in patients with Acute Myeloid Leukemia (AML)
Brief Description  
Primary: 1. Determine the efficac and tolerability of the combination of atezolizumab and an HMA in naive AML patients who are unfit to receive standard induction chemotherapy or relapsed/ refractory AML patients. 2. To determine the recommended Phase II dose and schedule of atezolizumab in combination with an HMA.
Who may be Eligible  
Please contact us for eligibility criteria.
Speciality/Disorder  
Leukemia, not otherwise specified
Status  
OPEN
Start Date  
04/07/2017
IRB Number  
00019062
Principal Investigator  
Grunwald, Michael Richard
Contact Name  
Carolyn Lehman

For More Information, Contact  Carolyn  , Lehman
Phone:  980-442-5225 Fax:    
Email:  Carolyn.Lehman@carolinashealthcare.org
Address:1021 Morehead Medical Drive Suite 2200 Charlotte, 28204
Close